**Summary of HUTCHMED (China) Limiteds 2025 Interim Results**
HUTCHMED (China) Limited reported its 2025 interim results, highlighting significant growth driven by indication expansions and its Antibody-Targeted Therapy Conjugates (ATTC) platform. Key financial and operational highlights include
### **Financial Performance**
**Net Income**$455 million, significantly boosted by a $416.3 million divestment gain from the partial sale of a non-core joint venture stake.
**Revenue**Total consolidated revenue of $277.7 million, down 9% year-on-year due to lower China in-market sales, partially offset by flat FRUZAQLA® revenue.
**Cash Position**$1.36 billion as of June 30, 2025, strengthened by divestment proceeds.
### **Commercial Progress**
**ORPATHYS® (savolitinib)**Secured third lung cancer indication in China for EGFRm NSCLC patients with MET amplification, eligible for national reimbursement negotiation. Triggered an $11 million milestone payment from AstraZeneca.
**FRUZAQLA® (fruquintinib ex-China)**In-market sales by Takeda grew 25% to $162.8 million, with expanded geographical coverage to over 30 countries.
**ELUNATE® (fruquintinib China)**Sales declined to $43.0 million due to competitive pressures and salesforce restructuring, but growth has recently resumed.
### **Pipeline and Clinical Developments**
**ORPATHYS®**Positive results from SACHI and SAVANNAH trials presented at ASCO and ELCC, demonstrating superior progression-free survival (PFS) compared to chemotherapy. SAFFRON Phase III trial enrollment expected to complete in H2 2025.
**SULANDA® (surufatinib)**Phase II/III trial in metastatic pancreatic cancer progressing well, with data readout expected in H2 2025.
**ELUNATE®**Positive FRUSICA-2 Phase III results supported China approval submission for kidney cancer, with details to be presented at ESMO.
**ATTC Platform**New drug candidates selected, with clinical development planned for late 2025. Pre-clinical data to be presented at a scientific conference by year-end.
### **Strategic Initiatives**
**ATTC Platform**Expected to enrich the pipeline and provide partnership opportunities, with initial positive responses from potential collaborators.
**Regulatory Milestones**Multiple approvals and submissions, including savolitinib’s sNDA approval in China and tazemetostat’s conditional approval for follicular lymphoma.
**Collaboration**Progress in candidate IMG-007, with positive Phase IIa results in atopic dermatitis and alopecia areata, and ongoing Phase IIb studies.
### **Outlook**
**Revenue Guidance**Updated to $270 million - $350 million for 2025 due to phasing of milestone income and delays in sovleplenib’s NDA review.
**Growth Strategy**Focus on accelerating ATTC global development and exploring investment opportunities, leveraging strong cash resources.
### **Leadership Statements**
**Dr. Dan Eldar (Chairman)**Highlighted HUTCHMED’s strong balance sheet, robust operations, and the potential of the ATTC platform for future growth.
**Dr. Weiguo Su (CEO)**Emphasized key milestones achieved in H1 2025, including regulatory approvals and clinical trial progress, and anticipated sales growth in H2 2025.
### **Sustainability**
Published 2024 Sustainability Report, showcasing progress in ESG goals and climate action initiatives.
HUTCHMED remains focused on innovation, global expansion, and strategic partnerships to address unmet medical needs and drive sustainable growth.
| Metric | H1 2025 | H1 2024 | Change |
|---|---|---|---|
| Revenue | $277.7 million | $305.7 million | -9% |
| Net Income Attributable to HUTCHMED | $455.0 million | $25.8 million | +1663% |
| Cash, Cash Equivalents, and Short-Term Investments | $1,364.5 million | $836.1 million | +63% |
| Total Assets | $1,775.9 million | $1,274.2 million | +39% |
| Total Liabilities | $534.0 million | $502.3 million | +6% |
| Debt (Bank Borrowings) | $93.4 million | $82.8 million | +13% |
| R&D Expenses | $72.0 million | $95.3 million | -24% |
| S&A Expenses | $41.6 million | $57.8 million | -28% |